HLB Pep Co., Ltd. (KOSDAQ:196300)
South Korea · Delayed Price · Currency is KRW 7,340.00
+450.00 (6.53%)
At close: Apr 1, 2026
HLB Pep Revenue
In the year 2025, HLB Pep had annual revenue of 4.96B KRW, down -20.34%. HLB Pep had revenue of 1.47B in the quarter ending December 31, 2025, with 5.08% growth.
Revenue
4.96B
Revenue Growth
-20.34%
P/S Ratio
13.75
Revenue / Employee
n/a
Employees
n/a
Market Cap
68.21B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.96B | -1.27B | -20.34% |
| Dec 31, 2024 | 6.23B | 618.09M | 11.02% |
| Dec 31, 2023 | 5.61B | -3.05B | -35.23% |
| Dec 31, 2022 | 8.66B | -1.60B | -15.63% |
| Dec 31, 2021 | 10.27B | 1.75B | 20.56% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Choong Ang Vaccine Laboratory | 39.19B |
| Naturalendo Tech | 22.23B |
| Ark Solutions | 16.08B |
| ADBiotech | 14.57B |
| PanGen Biotech | 13.42B |
| EyeGene | 3.57B |
| SunBio,Inc. | 2.17B |
| Aptamer Sciences | 1.08B |